Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Alnylam Makes Board Changes

This article was originally published in Scrip

Executive Summary

RNAi therapeutics company, Alnylam Pharmaceuticals, Inc. has appointed Michael Bonney, current board member and former CEO of Cubist Pharmaceuticals, chair of its board of directors – effective Jan. 1, 2016. John Clarke, founding investor and current chair, will remain on the board as a director. Former chair and CEO of Allergan, David Pyott, has also been appointed to Alnylam's board – effective immediately. In addition to serving as Cubist's CEO and a member of its board, Bonney was also previously its president and chief operating officer. He has also held various positions at Biogen, Inc. and prior to this he was at Zeneca Pharmaceuticals. Bonney has been a director of Alnylam since 2014 and is currently a director of the Celgene Corporation, the Whitehead Institute for Biomedical Research and the Gulf of Maine Research Institute. Pyott was CEO of Allergan from 1998 to 2015 and prior to this he was the head of Novartis nutrition division and a member of the executive committee of Switzerland-based Novartis AG. He is a lead director and member of the board of Avery Dennison Corporation and the supervisory board of Royal Philips in the Netherlands.